Foundation and core beliefs
Our Ambition
Neurological disorders are devastating and complex conditions with limited treatment options. By applying our innovative platform technology, we seek to create novel solutions for life-changing therapeutics to patients in medical need.
Our Foundation
Our employees are the foundation for the growth and progress of Contera Pharma. We are agile, ambitious and committed to make a difference for patients. We seek synergies in partnerships and collaborations to accomplish our goals.
Our Science
We are focused on creating a de-risked portfolio of projects aimed at human validated targets. Our scientific capacity and pharma knowledge base serve as strong levers for unraveling both the molecular mechanisms as well as solving the pharmacological challenges in disease.
Recent News
March 14, 2025
Contera Pharma announces that CP0014753, a novel antisense oligonucleotide developed for the treatment of Canavan disease, is ready for IND-enabling studies
Contera Pharma A/S, a clinical-stage biotech company pioneering innovative treatments for neurological disorders, has announced the preclinical candidate nomination of CP0014753, a…
Read more
December 03, 2024
Contera Pharma Welcomes New Board Members to Drive Strategic Growth
[Hørsholm, Denmark – December 03, 2024] – Contera Pharma A/S, a clinical-stage biotech company pioneering treatments for neurological disorders, is proud to…
Read more
Contact us
Contera Pharma
Contera Pharma A/S
Venlighedsvej 4
2970 Hørsholm
Denmark
Thomas Sager, CEO
info@conterapharma.com